Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 224 in relapsed or refractory multiple myeloma
NCT02561962Phase 1Completed
- Sponsor
- Amgen
- Start
- Nov 2015
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of amg 224 in multiple myeloma (MM) (9 arms), sponsored by Amgen. Primary endpoints: Dose-Limiting Toxicity and Treatment-emergent Adverse Event up to 12 weeks. Started Nov 2015; status: completed.
02
Drugs
amg 224
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02561962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561962.